文献速递骨软组织肉瘤与黑色素瘤

同步临床III期黑色素瘤的新辅助伊匹木单抗联合纳武利尤单抗治疗

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
PubMed 文献 · Eur J Cancer · 2021-03-15

研究从OpACIN、OpACIN-neo和PRADO三项新辅助试验中筛选出同步临床III期黑色素瘤患者,均接受伊匹木单抗联合纳武利尤单抗治疗,另纳入1例试验外病例。共7例患者中,6例原发灶或卫星灶与淋巴结转移灶的病理缓解一致,1例两处病灶一致进展并出现IV期疾病。提示新辅助免疫治疗前或无需对原发灶或卫星灶行 upfront 手术。

要点

  • 原发灶或卫星灶对新辅助伊匹木单抗联合纳武利尤单抗的病理缓解与淋巴结转移灶一致。
  • 7例中6例缓解一致,1例两处病灶一致进展并出现IV期疾病。
  • 结果提示新辅助治疗前可能无需对原发灶或卫星灶行 upfront 手术。

核心结论

  • 新辅助伊匹木单抗联合纳武利尤单抗后,原发灶或卫星灶的病理缓解与淋巴结转移灶一致,提示新辅助治疗前或无需对这些病灶行 upfront 手术。

研究设计与样本

  • 从OpACIN、OpACIN-neo和PRADO三项新辅助试验中筛选同步临床III期黑色素瘤患者,均接受伊匹木单抗联合纳武利尤单抗治疗,另纳入1例试验外病例,共7例。

主要发现

  • 7例患者中,6例原发灶或卫星灶与淋巴结转移灶的病理缓解一致。
  • 1例原发灶和淋巴结病灶一致进展,并在新辅助治疗期间出现IV期疾病,未行切除。

临床怎么用

  • 对于同步临床III期黑色素瘤,新辅助伊匹木单抗联合纳武利尤单抗前或可暂不切除原发灶或卫星灶,待新辅助治疗后与淋巴结清扫同期进行。

局限性

  • 样本量仅7例,证据有限,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impressive relapse-free survival in patients with nodal macroscopic stage III melanoma. Whether primary site melanoma and in-transit metastases respond similarly to lymph node metastases with neoadjuvant immunotherapy is largely unknown. Such data would clarify whether surgical excision of these melanoma lesions should be performed before neoadjuvant therapy or whether it could be deferred and performed in conjunction with lymphadenectomy following neoadjuvant immunotherapy. PATIENTS: Patients with synchronous clinical stage III melanoma were identified from the OpACIN, OpACIN-neo and PRADO neoadjuvant trials, where all patients were treated with ipilimumab plus nivolumab. An additional case treated outside those clinical trials was included. RESULTS: Seven patients were identified; six patients had a concordant response in primary site melanoma lesions or in-transit metastasis and the lymph node metastases. One patient had concordant progression in both the primary and nodal tumour lesions and developed stage IV disease during neoadjuvant treatment, and thus, no resection was performed. CONCLUSION: Pathologic response following neoadjuvant ipilimumab plus nivolumab in primary site melanoma lesions or in-transit metastasis is concordant with a response in the lymph node metastases, indicating that there may be no need to perform upfront surgery to these melanoma lesions prior to neoadjuvant treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Versluis JM, Reijers ILM, Rozeman EA, et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021. PMID: 33735809. doi:10.1016/j.ejca.2021.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。